{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T05:33:08Z","timestamp":1740202388861,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ariel Scientific Innovations (ASI) Ltd., Ariel University, Israel","award":["\/","\/","\/"],"award-info":[{"award-number":["\/","\/","\/"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04088-5","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:02:44Z","timestamp":1732190564000},"page":"1050-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells"],"prefix":"10.1007","volume":"87","author":[{"given":"Giusy","family":"Elia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Tkachenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipak","family":"Walunj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Botrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Gellerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"4088_CR1","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388, 2783\u20132795 (2016)","journal-title":"Lancet"},{"key":"4088_CR2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 317, 1338\u20131348 (2017)","journal-title":"JAMA"},{"issue":"Suppl 1","key":"4088_CR3","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","volume":"9","author":"SM Ferrari","year":"2020","unstructured":"S.M. Ferrari, G. Elia, F. Ragusa, I. Ruffilli, C. La Motta, S.R. Paparo, A. Patrizio, R. Vita, S. Benvenga, G. Materazzi, P. Fallahi, A. Antonelli, Novel treatments for anaplastic thyroid carcinoma. Gland. Surg. 9(Suppl 1), S28\u2013S42 (2020)","journal-title":"Gland. Surg."},{"key":"4088_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"L. Fugazzola, R. Elisei, D. Fuhrer, B. Jarzab, S. Leboulleux, K. Newbold, J. Smit, 2019 European Thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid. J. 8, 227\u2013245 (2019)","journal-title":"Eur. Thyroid. J."},{"key":"4088_CR5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"R.C. Smallridge, K.B. Ain, S.L. Asa, K.C. Bible, J.D. Brierley, K.D. Burman, E. Kebebew, N.Y. Lee, Y.E. Nikiforov, M.S. Rosenthal, M.H. Shah, A.R. Shaha, R.M. Tuttle, American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104\u20131139 (2012)","journal-title":"Thyroid"},{"key":"4088_CR6","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.3390\/ijms23105731","volume":"23","author":"F Ragusa","year":"2022","unstructured":"F. Ragusa, S.M. Ferrari, G. Elia, S.R. Paparo, E. Balestri, C. Botrini, A. Patrizio, V. Mazzi, G. Guglielmi, R. Foddis, C. Spinelli, S. Ulisse, A. Antonelli, P. Fallahi, Combination strategies involving immune checkpoint inhibitors and Tyrosine Kinase or BRAF inhibitors in aggressive thyroid cancer. Int. J. Mol. Sci. 23, 5731 (2022)","journal-title":"Int. J. Mol. Sci."},{"key":"4088_CR7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"M.E. Cabanillas, M. Ryder, C. Jimenez, Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev. 40, 1573\u20131604 (2019)","journal-title":"Endocr. Rev."},{"key":"4088_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/ERC-08-0154","volume":"16","author":"RC Smallridge","year":"2009","unstructured":"R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer. 16, 17\u201344 (2009)","journal-title":"Endocr. Relat. Cancer."},{"key":"4088_CR9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/14656566.2022.2030704","volume":"23","author":"G Elia","year":"2022","unstructured":"G. Elia, S.M. Ferrari, F. Ragusa, S.R. Paparo, V. Mazzi, S. Ulisse, S. Benvenga, A. Antonelli, P. Fallahi, Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. Expert. Opin. Pharmacother. 23, 599\u2013610 (2022)","journal-title":"Expert. Opin. Pharmacother."},{"key":"4088_CR10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","volume":"79","author":"P Fallahi","year":"2022","unstructured":"P. Fallahi, S.M. Ferrari, M.R. Galdiero, G. Varricchi, G. Elia, F. Ragusa, S.R. Paparo, S. Benvenga, A. Antonelli, Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin. Cancer Biol. 79, 180\u2013196 (2022)","journal-title":"Semin. Cancer Biol."},{"key":"4088_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers15010179","volume":"15","author":"J Yuan","year":"2022","unstructured":"J. Yuan, Y. Guo, Targeted therapy for anaplastic thyroid carcinoma: advances and management. Cancers 15, 179 (2022)","journal-title":"Cancers"},{"key":"4088_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","volume":"12","author":"C Pottier","year":"2020","unstructured":"C. Pottier, M. Fresnais, M. Gilon, G. J\u00e9rusalem, R. Longuesp\u00e9e, N.E. Sounni, Tyrosine Kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers 12, 731 (2020)","journal-title":"Cancers"},{"key":"4088_CR13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569\u2013580 (2011)","journal-title":"Nat. Rev. Endocrinol."},{"key":"4088_CR14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Pe\u00f1a, I. Moln\u00e1r, M.J. Schlumberger, DECISION investigators.: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319\u2013328 (2014)","journal-title":"Lancet"},{"key":"4088_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/s13044-020-00091-w","volume":"13","author":"S De Leo","year":"2020","unstructured":"S. De Leo, M. Trevisan, L. Fugazzola, Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 13, 17 (2020)","journal-title":"Thyroid Res."},{"key":"4088_CR16","first-page":"711","volume":"39","author":"H Yi","year":"2018","unstructured":"H. Yi, T. Ye, M. Ge, M. Yang, L. Zhang, S. Jin, X. Ye, B. Long, L. Li, Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer. Oncol. Rep. 39, 711\u2013720 (2018)","journal-title":"Oncol. Rep."},{"key":"4088_CR17","volume-title":"Phase II trial of sorafenib in patients with advanced thyroid cancer","author":"SM Keefe","year":"2011","unstructured":"S.M. Keefe, A.B. Troxel, S. Rhee, K. Puttaswamy, P.J. O\u2019Dwyer, L.A. Loevner, S.J. Mandel, M.S. Brose. Phase II trial of sorafenib in patients with advanced thyroid cancer. (ASCO Annual Meeting, Pennsylvania, Philadelphia), 2011). 20 May"},{"key":"4088_CR18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-12-0405","volume":"167","author":"TC Schneider","year":"2012","unstructured":"T.C. Schneider, R.M. Abdulrahman, E.P. Corssmit, H. Morreau, J.W. Smit, E. Kapiteijn, Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur. J. Endocrinol. 167, 643\u2013650 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"4088_CR19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","volume":"23","author":"P Savvides","year":"2013","unstructured":"P. Savvides, G. Nagaiah, P. Lavertu, P. Fu, J.J. Wright, R. Chapman, J. Wasman, A. Dowlati, S.C. Remick, Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid 23, 600\u2013604 (2013)","journal-title":"Thyroid"},{"key":"4088_CR20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cen.12057","volume":"78","author":"V Marotta","year":"2013","unstructured":"V. Marotta, V. Ramundo, L. Camera, Del Prete, M. Fonti, R. Esposito, R. Palmieri, G. Salvatore, M. Vitale, M. Colao, A. Faggiano, A.: Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin. Endocrinol. 78, 760\u2013767 (2013)","journal-title":"Clin. Endocrinol."},{"issue":"Suppl 1","key":"4088_CR21","doi-asserted-by":"crossref","first-page":"vi112","DOI":"10.1093\/annonc\/mdz338.094","volume":"30","author":"S Takahashi","year":"2019","unstructured":"S. Takahashi, M. Tahara, K. Ito, M. Tori, Y. Sakata, M. Ishii, A. Yoishida, Efficacy and safety of lenvatinib in 124 Japanese patients with anaplastic thyroid cancer. Ann. Oncol. 30(Suppl 1), vi112 (2019)","journal-title":"Ann. Oncol."},{"key":"4088_CR22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"S. Takahashi, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano, L. Inagaki, K. Toda, T. Enokida, H. Minami, Y. Imamura, N. Fukuda, T. Sasaki, T. Suzuki, H. Ikezawa, C.E. Dutcus, M. Tahara, A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 15, 717\u2013726 (2019)","journal-title":"Future Oncol."},{"key":"4088_CR23","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","volume":"21","author":"A Nair","year":"2015","unstructured":"A. Nair, S.J. Lemery, J. Yang, A. Marathe, L. Zhao, H. Zhao, X. Jiang, K. He, G. Ladouceur, A.K. Mitra, L. Zhou, E. Fox, S. Aungst, W. Helms, P. Keegan, R. Pazdur, FDA approval summary: Lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin. Cancer Res. 21, 5205\u20135208 (2015)","journal-title":"Clin. Cancer Res."},{"key":"4088_CR24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015)","journal-title":"N. Engl. J. Med."},{"key":"4088_CR25","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"M.S. Brose, B. Robinson, S.I. Sherman, J. Krajewska, C.C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, J. Hernando, L. Faoro, K. Banerjee, J.W. Oliver, B. Keam, J. Capdevila, Caboantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1126\u20131138 (2021)","journal-title":"Lancet Oncol."},{"key":"4088_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2023.0463","volume":"34","author":"J Capdevila","year":"2024","unstructured":"J. Capdevila, J. Krajewska, J. Hernando, B. Robinson, S.I. Sherman, B. Jarzab, C.C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, D. Williamson, R. Levytskyy, J. Oliver, B. Keam, M.S. Brose, Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: a Subgroup Analysis of the COSMIC-311 Study. Thyroid 34, 347\u2013359 (2024)","journal-title":"Thyroid"},{"key":"4088_CR27","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-22-0873","volume":"28","author":"ES Duke","year":"2022","unstructured":"E.S. Duke, A.K. Barone, S. Chatterjee, P.S. Mishra-Kalyani, Y.L. Shen, E. Isikwei, H. Zhao, Y. Bi, J. Liu, N.A. Rahman, E. Wearne, J.K. Leighton, M. Stephenson, I. Ojofeitimi, B. Scepura, A. Nair, R. Pazdur, J.A. Beaver, H. Singh, FDA approval summary: Cabozantinib for differentiated thyroid cancer. Clin. Cancer Res. 28, 4173\u20134177 (2022)","journal-title":"Clin. Cancer Res."},{"key":"4088_CR28","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","volume":"35","author":"ME Cabanillas","year":"2017","unstructured":"M.E. Cabanillas, J.A. de Souza, S. Geyer, L.J. Wirth, M.E. Menefee, S.V. Liu, K. Shah, J. Wright, M.H. Shah, Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter Phase II international thyroid oncology group trial. J. Clin. Oncol. 35, 3315\u20133321 (2017)","journal-title":"J. Clin. Oncol."},{"key":"4088_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J. Clin. Oncol. 36, 7\u201313 (2018)","journal-title":"J. Clin. Oncol."},{"key":"4088_CR30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C.C. Zielinski, M.E. Cabanillas, A. Boran, P. Ilankumaran, P. Burgess, T. Romero Salas, B. Keam, Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33, 406\u2013415 (2022)","journal-title":"Ann. Oncol."},{"key":"4088_CR31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2217\/ije-2016-0007","volume":"3","author":"ME Cabanillas","year":"2016","unstructured":"M.E. Cabanillas, N.L. Busaidy, S.A. Khan, G.B. Gunn, R. Dadu, S.N. Rao, S.G. Waguespack, Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. Int. J. Endocr. Oncol. 3, 221\u2013233 (2016)","journal-title":"Int. J. Endocr. Oncol."},{"key":"4088_CR32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/thy.2018.0060","volume":"28","author":"ME Cabanillas","year":"2018","unstructured":"M.E. Cabanillas, R. Ferrarotto, A.S. Garden, S. Ahmed, N.L. Busaidy, R. Dadu, M.D. Williams, H. Skinner, G.B. Gunn, H. Grosu, P. Iyer, M.C. Hofmann, M. Zafereo, Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28, 945\u2013951 (2018)","journal-title":"Thyroid"},{"key":"4088_CR33","doi-asserted-by":"crossref","unstructured":"Lenvatinib approved for certain thyroid cancers. Cancer Discov. 5, 338 (2015)","DOI":"10.1158\/2159-8290.CD-NB2015-029"},{"key":"4088_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113811","volume":"225","author":"D Walunj","year":"2021","unstructured":"D. Walunj, E. Thankarajan, C. Prasad, H. Tuchinsky, S. Baldan, M.Y. Sherman, G. Gellerman, Targeted methylation facilitates DNA double strand breaks and enhances cancer suppression: A DNA intercalating\/methylating dual-action chimera Amonafidazene. Eur. J. Med. Chem. 225, 113811 (2021)","journal-title":"Eur. J. Med. Chem."},{"key":"4088_CR35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/ERC-17-0045","volume":"24","author":"F Marano","year":"2017","unstructured":"F. Marano, R. Frairia, L. Rinella, M. Argenziano, B. Bussolati, C. Grange, R. Mastrocola, I. Castellano, L. Berta, R. Cavalli, M.G. Catalano, Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model. Endocr. Relat. Cancer 24, 275\u2013286 (2017)","journal-title":"Endocr. Relat. Cancer"},{"key":"4088_CR36","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2967\/jnumed.106.038612","volume":"48","author":"KI Kim","year":"2007","unstructured":"K.I. Kim, J.H. Kang, J.K. Chung, Y.J. Lee, J.M. Jeong, D.S. Lee, M.C. Lee, Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J. Nucl. Med. 48, 1553\u20131561 (2007)","journal-title":"J. Nucl. Med."},{"key":"4088_CR37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","volume":"84","author":"DR Newell","year":"2001","unstructured":"D.R. Newell, Flasks, fibres and flanks\u2013pre-clinical tumour models for predicting clinical antitumour activity. Br. J. Cancer 84, 1289\u20131290 (2001)","journal-title":"Br. J. Cancer"},{"key":"4088_CR38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF02686104","volume":"35","author":"RD Blumenthal","year":"2007","unstructured":"R.D. Blumenthal, D.M. Goldenberg, Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol. Biotechnol. 35, 185\u2013197 (2007)","journal-title":"Mol. Biotechnol."},{"key":"4088_CR39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12020-015-0717-4","volume":"53","author":"P Fallahi","year":"2016","unstructured":"P. Fallahi, S.M. Ferrari, C. La Motta, G. Materazzi, G. Bocci, F. Da Settimo, P. Miccoli, A. Antonelli, CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoural activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Endocrine 53, 136\u2013144 (2016)","journal-title":"Endocrine"},{"key":"4088_CR40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3889\/oamjms.2016.086","volume":"4","author":"T Makazlieva","year":"2016","unstructured":"T. Makazlieva, O. Vaskova, V. Majstorov, Etiopathogenesis of differentiated thyroid carcinomas. Open Access Maced. J. Med. Sci. 4, 517\u2013522 (2016)","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"4088_CR41","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ijms24032398","volume":"24","author":"SM Ferrari","year":"2023","unstructured":"S.M. Ferrari, G. Elia, F. Ragusa, S.R. Paparo, V. Mazzi, A. Patrizio, S. Piaggi, E. Baldini, M. Centanni, C. La Motta, A. Antonelli, P. Fallahi, Antineoplastic activity of pazopanib in anaplastic thyroid cancer in primary culture. Int. J. Mol. Sci. 24, 2398 (2023)","journal-title":"Int. J. Mol. Sci."},{"key":"4088_CR42","first-page":"2306","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, G. Bocci, T. Di Desidero, I. Ruffilli, G. Elia, F. Ragusa, A. Fioravanti, P. Orlandi, S.R. Paparo, A. Patrizio, S. Piaggi, C. La Motta, S. Ulisse, E. Baldini, G. Materazzi, P. Miccoli, A. Antonelli, P. Fallahi, Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol. Rep. 39, 2306\u20132314 (2018)","journal-title":"Oncol. Rep."},{"key":"4088_CR43","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.3390\/ijms25126734","volume":"25","author":"SM Ferrari","year":"2024","unstructured":"S.M. Ferrari, F. Ragusa, G. Elia, V. Mazzi, E. Balestri, C. Botrini, L. Rugani, A. Patrizio, S. Piaggi, C. La Motta, S. Ulisse, C. Virili, A. Antonelli, P. Fallahi, Antineoplastic effect of ALK inhibitor crizotinib in primary human anaplastic thyroid cancer cells with STRN-ALK fusion in vitro. Int. J. Mol. Sci. 25, 6734 (2024)","journal-title":"Int. J. Mol. Sci."},{"key":"4088_CR44","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2265.2008.03415.x","volume":"70","author":"A Antonelli","year":"2009","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, M. Minuto, R. Giannini, I. Marchetti, L. Barani, F. Basolo, E. Ferrannini, P. Miccoli, Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin. Endocrinol. 70, 946\u2013953 (2009)","journal-title":"Clin. Endocrinol."},{"key":"4088_CR45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EJE-08-0190","volume":"159","author":"A Antonelli","year":"2008","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, E. Ferrannini, Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol. 159, 283\u2013291 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"4088_CR46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2265.2008.03182.x","volume":"69","author":"A Antonelli","year":"2008","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, L. Barani, I. Marchetti, E. Ferrannini, P. Miccoli, Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin. Endocrinol. 69, 148\u201352 (2008)","journal-title":"Clin. Endocrinol."},{"key":"4088_CR47","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.1210\/jc.2013-2321","volume":"99","author":"A Antonelli","year":"2014","unstructured":"A. Antonelli, G. Bocci, P. Fallahi, C. La Motta, S.M. Ferrari, C. Mancusi, A. Fioravanti, T. Di Desidero, S. Sartini, A. Corti, S. Piaggi, G. Materazzi, C. Spinelli, G. Fontanini, R. Danesi, F. Da Settimo, P. Miccoli, CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 99, E572\u2013E581 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4088_CR48","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1210\/jc.2011-1987","volume":"97","author":"A Antonelli","year":"2012","unstructured":"A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, I. Ruffilli, A. Di Domenicantonio, A. Fioravanti, S. Sartini, M. Minuto, S. Piaggi, A. Corti, G. Al\u00ec, T. Di Desidero, P. Berti, G. Fontanini, R. Danesi, F. Da Settimo, P. Miccoli, CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 97, E528\u2013E536 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4088_CR49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","volume":"11","author":"MV Berridge","year":"2005","unstructured":"M.V. Berridge, P.M. Herst, A.S. Tan, Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 11, 127\u2013152 (2005)","journal-title":"Biotechnol. Annu. Rev."},{"key":"4088_CR50","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1677\/ERC-08-0337","volume":"16","author":"A Antonelli","year":"2009","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, S. Frascerra, S. Piaggi, S. Gelmini, C. Lupi, M. Minuto, P. Berti, S. Benvenga, F. Basolo, C. Orlando, P. Miccoli, Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr. Relat. Cancer. 16, 1299\u20131311 (2009)","journal-title":"Endocr. Relat. Cancer."},{"key":"4088_CR51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nprot.2006.458","volume":"2","author":"I Schmid","year":"2007","unstructured":"I. Schmid, C. Uittenbogaart, B.D. Jamieson, Live-cell assay for detection of apoptosis by dual-laser flow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nat. Protoc. 2, 187\u2013190 (2007)","journal-title":"Nat. Protoc."},{"key":"4088_CR52","first-page":"2225","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, G. Bocci, T. Di Desidero, G. Elia, I. Ruffilli, F. Ragusa, P. Orlandi, S.R. Paparo, A. Patrizio, S. Piaggi, C. La Motta, S. Ulisse, E. Baldini, G. Materazzi, P. Miccoli, A. Antonelli, P. Fallahi, Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol. Rep. 39, 2225\u20132234 (2018)","journal-title":"Oncol. Rep."},{"key":"4088_CR53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fendo.2018.00764","volume":"9","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, C. La Motta, G. Elia, F. Ragusa, I. Ruffilli, L. Quattrini, S.R. Paparo, S. Piaggi, A. Patrizio, S. Ulisse, E. Baldini, G. Materazzi, P. Fallahi, A. Antonelli, Antineoplastic effect of Lenvatinib and Vandetanib in primary anaplastic thyroid cancer cells obtained from biopsy or fine needle aspiration. Front. Endocrinol. 9, 764 (2018)","journal-title":"Front. Endocrinol."},{"key":"4088_CR54","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1","volume":"60","author":"JH Kim","year":"1987","unstructured":"J.H. Kim, R.D. Leeper, Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60, 2372\u20132375 (1987)","journal-title":"Cancer"},{"key":"4088_CR55","doi-asserted-by":"publisher","unstructured":"A. Bisht, D. Avinash, K.K. Sahu, P. Patel, G. Das Gupta, B.D. Kurmi, A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Deliv. Transl. Res. (2024). https:\/\/doi.org\/10.1007\/s13346-024-01648-0","DOI":"10.1007\/s13346-024-01648-0"},{"key":"4088_CR56","first-page":"6675","volume":"15","author":"C Li","year":"2023","unstructured":"C. Li, S. Qiao, M. Kang, X. Gao, Z. Li, Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials. Am. J. Transl. Res. 15, 6675\u20136689 (2023)","journal-title":"Am. J. Transl. Res."},{"key":"4088_CR57","volume":"11","author":"W Zeng","year":"2023","unstructured":"W. Zeng, Y. Luo, D. Gan, Y. Zhang, H. Deng, G. Liu, Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer. Front. Bioeng. Biotechnol. 11, 1271420 (2023)","journal-title":"Front. Bioeng. Biotechnol."},{"key":"4088_CR58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fphar.2020.00632","volume":"11","author":"B Lin","year":"2020","unstructured":"B. Lin, B. Lu, I.Y. Hsieh, Z. Liang, Z. Sun, Y. Yi, W. Lv, W. Zhao, J. Li, Synergy of GSK-J4 With Doxorubicin in KRAS-mutant anaplastic thyroid cancer. Front. Pharmacol. 11, 632 (2020)","journal-title":"Front. Pharmacol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04088-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04088-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:20:36Z","timestamp":1740147636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04088-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4088"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04088-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee for Clinical trials of Pisa University Hospital (date of approval 18 November 2012).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}}]}}